Living Donor Liver Transplant (LDLT) in Bangalore
Liver failure is not the end — it is a signal for renewal. Living Donor Liver Transplant (LDLT) is the gold standard treatment for end-stage liver disease in India, where deceased donor organs are critically scarce. By using a partial liver from a healthy, voluntary living relative, we bypass the years-long deceased donor waiting list and operate before the patient becomes too critically unwell to withstand surgery. This is not just an operation. It is a second life — for both the recipient and the family that chooses to give it.
India performs more LDLT procedures than any country in the world except South Korea — a reflection of both the burden of end-stage liver disease in our population and the cultural willingness of Indian families to step forward as living donors. Dr. Srinivas Bojanapu brings international-standard LDLT expertise to Bangalore, performing these complex surgeries at Kauvery Hospital with full pre-operative planning and long-term follow-up through Dhaara Speciality Hospital, Yelahanka.
When Is a Liver Transplant Actually Needed?
Liver transplantation is not a first resort — it is the last and most definitive therapy when the liver can no longer sustain life through medical management alone. Understanding when transplant becomes necessary requires familiarity with the MELD score (Model for End-stage Liver Disease) — the internationally validated scoring system that quantifies liver failure severity and prioritises patients for transplantation.
The MELD score is calculated using three blood tests: serum bilirubin (jaundice marker), serum creatinine (kidney function), and INR (clotting ability). A higher score reflects greater liver failure and shorter expected survival without transplant. In India, where deceased donor organs are extremely scarce, LDLT from a living relative offers the only realistic escape from the mortality associated with progressive liver failure.
MELD Score: Understanding Your Number
| MELD Score | Classification | 3-Month Mortality (Without Transplant) | Transplant Recommendation |
|---|---|---|---|
| 6–9 | Mild liver disease | < 4% | Medical management; close monitoring |
| 10–19 | Moderate liver disease | 6–20% | Transplant evaluation initiated |
| 20–29 | Severe liver failure | 20–45% | Active LDLT workup; donor assessment begins |
| 30+ | Critical / Urgent | 52–71% | Urgent LDLT; time-sensitive donor clearance |
Conditions That Lead to LDLT
Cirrhosis from any cause — Hepatitis B, Hepatitis C, MASLD/NASH, alcohol-related liver disease — is the most common indication. Other indications include hepatocellular carcinoma (HCC) within Milan criteria, acute liver failure (from drugs, viruses, or autoimmune disease), Wilson's disease, primary biliary cholangitis, primary sclerosing cholangitis, and metabolic liver diseases such as haemochromatosis and alpha-1 antitrypsin deficiency.
Why LDLT Over Deceased Donor Transplant in India?
In Western countries, the deceased donor pool — organs from brain-dead individuals — provides the majority of liver transplants. In India, deceased donation rates remain critically low at approximately 0.8 per million population, compared to over 40 per million in Spain. For the average Indian patient, waiting for a deceased donor liver means waiting years — during which MELD rises, complications accumulate, and surgical risk increases. LDLT, using a partial liver from a healthy living relative, is the only practical pathway to transplant for most Indian families.
The newer MELD-Na score incorporates serum sodium (Na) as a fourth variable, improving prediction of 90-day mortality in patients with ascites. A falling sodium level in a cirrhotic patient with ascites — called dilutional hyponatraemia — is a strong independent predictor of pre-transplant mortality and escalates the urgency of LDLT evaluation. We assess MELD-Na at every clinic visit for all cirrhosis patients to determine optimal transplant timing.
The Donor: Safety Is Our Absolute Priority
The first and most important principle of living donor liver transplantation is this: a healthy person is voluntarily undergoing major surgery to save a life, and their safety is our moral, ethical, and legal priority — above every other consideration. No recipient benefit can justify donor harm. Global data from over 10,000 living liver donors confirms that mortality risk in an experienced centre is less than 0.2% — comparable to other major elective abdominal surgeries — and serious complication rates are below 5%.
The donor evaluation process is deliberately rigorous, thorough, and unhurried. We do not simply look for reasons to approve a donor. We look for any reason — medical, anatomical, psychological, or social — that would make donation unsafe for that individual. Our commitment is to return the donor to their family healthier than they arrived.
Comprehensive Donor Eligibility Criteria
Every prospective donor undergoes a structured multi-phase evaluation before a final decision is made.
Who Can Donate — Inclusion Criteria
Age: 18 to 55 years. Relationship: Close relative — spouse, son, daughter, sibling, or parent. BMI: Ideally below 28; obesity increases hepatic steatosis risk. Blood Group: ABO-compatible preferred; ABO-incompatible protocol available (see below). Liver Volume: Adequate right lobe volume on CT volumetry (GRWR ≥ 0.8%). Hepatic Anatomy: Suitable vascular and biliary anatomy on MRI cholangiography.
Who Cannot Donate — Absolute Exclusions
Active infection: HIV, active Hepatitis B or C. Metabolic disease: Type 1 or 2 diabetes on medication. Cardiovascular disease: Any coronary artery disease, heart failure, or poorly controlled hypertension. Pregnancy: Absolute contraindication. Hepatic steatosis: Macrosteatosis exceeding 20% on liver biopsy. Coagulation disorders: Inherited thrombophilia or bleeding disorder. Malignancy: Any active cancer diagnosis.
Psychological & Social Evaluation
Every donor undergoes an independent psychiatric assessment to confirm the decision is fully voluntary, free from family pressure or financial coercion, and made with complete informed consent. A social worker meets the donor separately from the recipient's family. The Authorization Committee interview (see Legal Process section) provides an additional independent safeguard against coerced donation — a cornerstone of India's THOA Act framework.
The Fatty Liver Problem in Donors
Hepatic steatosis is increasingly common in Indian donors due to rising rates of MASLD. Macrosteatosis above 20% significantly impairs graft function — a fatty liver fails to regenerate adequately and carries higher primary non-function risk. When a prospective donor has 15–25% steatosis, we implement a structured 4–6 week dietary intervention (caloric restriction, fructose elimination, daily walking) followed by repeat biopsy. Steatosis below 10% confirms donor eligibility.
Donor Workup — Step by Step
Phase 1: Blood & Metabolic Screening
Complete blood count, liver function tests, kidney function, coagulation profile, fasting glucose, HbA1c, lipid panel, thyroid function, viral serology (HIV, HBV, HCV, CMV, EBV), ABO blood group, and tumour markers. This phase eliminates systemic contraindications before any invasive testing.
Phase 2: Hepatic Imaging
Triple-phase CT of the abdomen with CT Volumetry software precisely calculates total liver volume, right lobe volume (the graft), and the future liver remnant (FLR). MRI with MRCP maps biliary anatomy — detecting variant bile duct configurations that require modified surgical technique. MRI-PDFF quantifies hepatic fat content non-invasively.
Phase 3: Cardiopulmonary Assessment
ECG, 2D echocardiogram, and stress test where indicated confirm cardiac fitness for major surgery under general anaesthesia lasting 6–8 hours. Pulmonary function tests and anaesthesia review complete the cardiopulmonary clearance.
Phase 4: Liver Biopsy (If Required)
When imaging suggests borderline hepatic fat (10–25%), a percutaneous liver biopsy under ultrasound guidance provides the definitive histological steatosis quantification. This is the only way to accurately confirm that the graft is safe to donate and will function adequately in the recipient.
Blood Group Matching & ABO-Incompatible (ABOi) Transplant
Blood group compatibility between donor and recipient was historically a strict requirement for liver transplantation. Today, advances in immunosuppression have opened the door to ABO-incompatible (ABOi) LDLT — a critical development for Indian families where a perfect blood group match may not exist among eligible donors.
Gives to A, B, AB, O
When no blood-group compatible donor is available within the family, we can still perform transplantation using an ABO-incompatible graft through a structured desensitisation protocol. This involves: (1) Rituximab — a monoclonal antibody that depletes B-lymphocytes (the cells that produce anti-blood-group antibodies) administered 2 weeks before surgery. (2) Plasmapheresis — a blood-filtering technique that physically removes the harmful antibodies from the recipient's circulation in the days before and after surgery. (3) Intravenous Immunoglobulin (IVIG) — to modulate residual immune responses. ABOi LDLT outcomes in experienced centres now approach ABO-compatible results, with 1-year recipient survival exceeding 85% in published series from South Korean and Indian high-volume centres.
The primary risk unique to ABOi transplantation is antibody-mediated rejection — where residual anti-A or anti-B antibodies attack the hepatic microvasculature, causing hepatic artery thrombosis or diffuse intrahepatic biliary strictures. This risk is highest in the first 2 weeks post-transplant. Intensive monitoring with daily Doppler ultrasound of hepatic vessels, protocol biopsies at Days 7 and 14, and titrated plasmapheresis based on antibody titre levels form the cornerstone of early post-operative ABOi management.
The Science of Volume Matching — GRWR
Blood group compatibility is only one dimension of donor-recipient matching. The more nuanced and technically demanding challenge is volumetric matching — ensuring the donated liver piece is precisely sized to sustain the recipient's metabolic demands while leaving the donor with a safe volume of liver remnant.
The Graft-to-Recipient Weight Ratio (GRWR) is the single most important volumetric parameter in LDLT planning. It is calculated as: Graft Weight (g) ÷ Recipient Body Weight (kg). The donated liver piece must achieve a minimum GRWR of 0.8% to provide adequate functional mass. Below this threshold, the graft is at risk of Small-for-Size Syndrome (SFSS) — a life-threatening condition where the undersized graft cannot handle the high portal blood flow from the recipient's portal hypertensive circulation, leading to graft failure.
Example: A recipient weighing 75 kg requires a minimum graft weight of 600 grams (75 × 0.008). If the donor's right lobe on CT Volumetry measures only 520 grams, they are not a suitable donor for this recipient. We may then consider an Extended Left Lobe (including the caudate lobe) or a dual-graft approach where two donors each contribute a left lobe.
CT Volumetry — Pre-Operative Planning
Triple-phase CT with dedicated volumetry software calculates the total liver volume, the right lobe volume (our standard adult graft), the middle hepatic vein territory, and the future liver remnant (FLR) for the donor. The FLR must be at least 30% of the donor's total liver volume — the critical safety threshold below which the donor faces risk of post-hepatectomy liver failure. This calculation is done before we ever schedule the surgery.
Small-for-Size Syndrome — Prevention
When GRWR is borderline (0.6–0.8%), we use portal flow modulation techniques to reduce the excessive portal pressure transmitted to the small graft. These include splenic artery ligation, splenectomy, and porto-caval shunting. These manoeuvres "protect" the undersized graft from haemodynamic injury during the critical early post-operative period when regeneration has not yet occurred.
Right Lobe vs Left Lobe Donation
The Right Lobe (Segments 5–8) comprises 60–65% of total liver volume and is the standard graft for adult-to-adult LDLT, providing sufficient mass for most recipients. The Left Lateral Segment (Segments 2–3, approximately 20–25% of liver volume) is used for paediatric recipients, where a smaller graft is sufficient. The Extended Left Lobe (Segments 2–4 + caudate) is used in selected cases where right lobe donation would leave an inadequate donor remnant.
Dual Graft LDLT
In cases where a single donor cannot provide adequate graft volume — typically when both the recipient is large (body weight above 80 kg) and the donor is small — a dual graft approach uses left lateral segments from two separate living donors, implanted together to achieve combined adequate volume. This advanced technique requires exceptional surgical coordination and two separate donor teams operating simultaneously.
The Legal Process — India's THOA Act Safeguards
India has enacted some of the world's most rigorous legal protections for living organ donors through the Transplantation of Human Organs and Tissues Act (THOA), first enacted in 1994 and significantly strengthened in 2011. These laws exist to prevent organ trade, coerced donation, and exploitation of vulnerable individuals. Every LDLT case in India — without exception — must receive clearance from a government-appointed Authorization Committee before surgery proceeds.
Three-Phase Legal Clearance Protocol
Understanding this process eliminates anxiety and allows families to prepare documentation efficiently before transplant evaluation begins.
Phase 1: Medical Fitness Clearance
The hospital's internal transplant committee reviews all medical investigation reports for both donor and recipient. The transplant team signs a formal medical fitness certificate confirming that the donor is medically and psychologically fit to donate, the recipient is an appropriate LDLT candidate, and the surgery is medically indicated. This internal clearance is the prerequisite for submitting the legal application.
Phase 2: Relationship Proof & DNA Matching
Documentary proof of the relationship between donor and recipient is mandatory — birth certificates, marriage certificates, Aadhaar card, and family photograph. For all cases, HLA (Human Leukocyte Antigen) typing is performed as a laboratory-based DNA confirmation of biological relationship. For donors who are not immediate first-degree relatives (e.g., cousins, siblings-in-law), additional documentation and a mandatory DNA test are required before the committee will consider the case.
Phase 3: Authorization Committee Interview
The state government-appointed Authorization Committee — typically comprising a senior civil servant, a senior doctor not affiliated with the transplant centre, and a social worker — conducts a formal interview with the donor alone, without the recipient or the recipient's family present. The interview is video-recorded. The committee specifically probes for financial payment, family pressure, and complete informed understanding of the risks. Clearance is granted only when the committee is satisfied that donation is entirely voluntary.
Timelines by Relationship Category
Spouse, parent, child, sibling: Typically 5–7 working days from application submission. First cousin, aunt/uncle, grandparent: Requires DNA confirmation — allow 10–14 days. Near relative with documentation challenges: May require a second committee meeting — allow 2–3 weeks. Our transplant coordinator assists families in preparing complete documentation packages to avoid delays in this critical pathway.
The THOA framework has been instrumental in reducing illegal organ trade in India while simultaneously creating a safe, transparent pathway for genuine family-based donation. The committee interview is not an obstacle — it is your family's protection against future social pressure or guilt. Once clearance is granted, the donation stands on irrefutable legal ground.
The Surgery — Two Operating Theatres, One Mission
LDLT is among the most complex procedures in all of abdominal surgery. It involves two simultaneous operations in adjacent theatres — the donor hepatectomy and the recipient transplant — conducted by separate surgical teams working in precise coordination. The recipient surgery cannot begin until the donor liver is safely divided and confirmed viable, typically a 60–90 minute overlap period.
Donor Surgery — Right Hepatectomy
We typically remove the Right Lobe (Segments 5–8, comprising 60–65% of liver volume) for adult recipients. The liver is divided using a CUSA (Cavitron Ultrasonic Surgical Aspirator) — an ultrasonic device that selectively destroys liver parenchyma while preserving the biliary and vascular structures, dramatically reducing intraoperative blood loss. The gallbladder is removed simultaneously. The right hepatic vein, right portal vein, right hepatic artery, and right bile duct are individually divided, and the lobe is removed. Total duration: 5–7 hours.
Recipient Surgery — Explant & Implant
The recipient's native diseased liver is removed (total hepatectomy) — a technically demanding phase in a patient with portal hypertension and coagulopathy. The new donor graft is then implanted through four anastomoses performed in sequence: (1) Hepatic Vein — outflow of blood from the new liver. (2) Portal Vein — the main blood inflow bringing nutrients from the intestine. (3) Hepatic Artery — oxygenated blood supply, anastomosed under microscope magnification given vessel diameters of 2–4mm. (4) Bile Duct — drainage of bile into the small intestine via a Roux-en-Y hepaticojejunostomy. Total duration: 8–12 hours.
Robotic Donor Hepatectomy
At Kauvery Hospital, robotic-assisted donor hepatectomy is now available for selected donors. The robotic platform provides 3D magnification and wristed instrument dexterity that significantly improves precision during the critical liver parenchymal transection phase. The organ extraction incision is positioned low (similar to a C-section scar) rather than the traditional subcostal "Mercedes Benz" incision, offering significantly improved cosmesis and faster wound recovery for the donor.
Biliary Reconstruction — The Most Critical Anastomosis
Biliary complications — leaks and strictures — remain the most common technical complication after LDLT, occurring in 10–20% of cases even in expert centres. The bile duct anastomosis must be performed with extreme precision: tension-free, with good blood supply, and using fine absorbable sutures. Intraoperative cholangiography (bile duct X-ray) and indocyanine green (ICG) fluorescence imaging help confirm adequate biliary drainage before the abdomen is closed.
The Miracle of Liver Regeneration
The question every donor's family asks is: "How can someone survive with half a liver?" The answer reveals one of the most extraordinary phenomena in human biology. The liver is the only solid visceral organ in the human body capable of true hyperplastic regeneration — it does not merely stretch or hypertrophy; it grows entirely new hepatocytes, restoring mass and function to near-normal levels within weeks.
This regenerative capacity is driven by the interplay of hepatocyte growth factor (HGF), transforming growth factor alpha (TGF-α), interleukin-6, and the Wnt/β-catenin signalling pathway. Portal blood flow — increased proportionally when a large liver is suddenly reduced to 35–40% of its original volume — acts as the primary regenerative stimulus. The liver "senses" the mismatch between its functional demand and its current mass, and responds by entering a rapid proliferative cycle.
Rapid cell proliferation begins. Liver enzymes are transiently elevated — a normal regenerative signal, not a sign of damage. Bilirubin normalises quickly.
60–70% of original liver volume is restored on follow-up ultrasound. Donor energy levels return to near-normal. Dietary restrictions are largely lifted.
90%+ of liver volume and full metabolic function restored. Follow-up CT confirms complete anatomical regeneration. Donor returns to all normal activities including sport.
A landmark 2022 study published in Hepatology following 1,508 living liver donors over 10 years found that donor long-term liver function, quality of life, and all-cause mortality were indistinguishable from matched non-donor controls. Long-term liver function tests, Fibroscan stiffness scores, and cancer incidence were all equivalent between donors and the general population — confirming that right hepatectomy for donation, performed in a carefully selected and well-evaluated individual, carries no long-term hepatic health penalty.
Recovery Timeline — Donor & Recipient
Understanding the recovery pathway reduces anxiety and allows families to plan support systems, leave arrangements, and home care in advance. Both donor and recipient recoveries are managed with detailed written protocols provided at discharge from Kauvery Hospital, with all follow-up conducted at Dhaara Speciality Hospital for the convenience of North Bangalore families.
Detailed Recovery Milestones
Both the donor and recipient receive a personalised recovery roadmap. These are typical milestones for uncomplicated cases.
Donor — Hospital Phase (Days 1–7)
Epidural analgesia provides excellent pain control with minimal opioid use. Nasogastric tube removed on Day 1. Clear liquids begin Day 2; soft diet by Day 3. Drain removed when output confirms no bile leak — typically Day 4–5. Liver function tests monitored daily and are expected to peak at Day 2–3 before steadily normalising. Discharge on Day 5–7 when ambulatory, tolerating oral diet, and liver enzymes trending down.
Donor — Home Recovery (Weeks 2–6)
Wound care with dissolvable cosmetic sutures — no stitch removal needed. Gentle walking from Day 10 progressing to 30 minutes daily by Week 3. Desk work by Week 3–4. Driving by Week 4 (once off prescription painkillers). Light physical work by Week 6. Gym and strenuous exercise by Month 3 post-operative CT confirms full regeneration. No long-term dietary restriction. Zero lifelong medication.
Recipient — ICU & Hospital Phase (Days 1–15)
ICU monitoring for 3–5 days: daily Doppler ultrasound of hepatic vessels (hepatic artery thrombosis is the most feared early complication), liver function tests, coagulation profile, tacrolimus drug levels, and renal function. Immunosuppression is initiated with tacrolimus, mycophenolate mofetil, and a steroid taper. Biliary drain (if placed intraoperatively) monitored for bile output. Total hospital stay 12–15 days for uncomplicated recovery.
Recipient — Post-Discharge (Months 1–6)
Infection precautions: Avoid crowds, wear mask in public, no raw food for 3 months (immunosuppression risk). Clinic visits: Weekly for first month, fortnightly for Months 2–3, monthly thereafter. Medication adherence: Tacrolimus must be taken at exactly the same time every day — even a 2-hour delay can trigger rejection. Quality of life: Fully normal activities including work resume by Month 3–6 for most recipients.
Liver transplant recipients take tacrolimus (or cyclosporine) for life. This is non-negotiable. Missing doses — even occasionally — dramatically increases the risk of acute cellular rejection, which if undetected can progress to chronic rejection and graft loss. All recipients are educated about drug interactions: St John's Wort, rifampicin, and several antifungal drugs critically reduce tacrolimus levels; grapefruit juice significantly increases them. Every new medication prescribed by any doctor — including dentists — must be cross-checked with the transplant team before administration.
Paediatric Liver Transplantation in Bangalore
Children with end-stage liver disease face unique challenges compared to adults: smaller anatomy, different disease spectrum, and the requirement for precise graft size matching to a small recipient. Paediatric LDLT is one of the most rewarding procedures in transplant surgery — children with biliary atresia or metabolic liver diseases who undergo successful transplantation achieve near-normal long-term survival and development.
Indications in Children
Biliary Atresia is the most common paediatric LDLT indication — a condition where the bile ducts are absent or destroyed, causing progressive cirrhosis from birth. Other indications include Alagille syndrome, progressive familial intrahepatic cholestasis (PFIC), Wilson's disease presenting in childhood, tyrosinaemia, glycogen storage disease, and acute liver failure from viral hepatitis or drug toxicity.
Left Lateral Segment Graft for Children
For most paediatric recipients, the Left Lateral Segment (Segments 2–3) from a parent donor provides the correct graft size. This portion represents only 15–20% of the donor's liver, leaving the donor with an 80–85% remnant — the safest donor operation with the fastest regeneration. A parent donation to a child is both biologically optimal and legally straightforward under the THOA framework.
Most children with biliary atresia first undergo a Kasai portoenterostomy — a surgical procedure that restores bile drainage by connecting the liver directly to the small intestine. In approximately 50–60% of cases, the Kasai procedure provides adequate drainage to delay cirrhosis for years. When it fails — evidenced by persistent jaundice, poor growth, portal hypertension, or recurrent cholangitis — liver transplantation becomes necessary. The optimal transplant window is before the age of 2, when the child has sufficient weight for safe surgery but before nutritional failure and developmental delay become irreversible.
Long-Term Post-Transplant Management
Liver transplantation is not a cure — it is a lifelong medical commitment that transforms end-stage liver disease into a chronic, manageable condition requiring ongoing specialist oversight. The medical burden after transplant is substantial but predictable, and the quality of life achievable with good protocol adherence is excellent. Most recipients return to full employment, family life, travel, and recreational activities within 6 months of transplantation.
Rejection Surveillance
Acute cellular rejection (ACR) occurs in 15–25% of LDLT recipients in the first year, most commonly in the first 3 months. Early ACR presents as rising liver enzymes and is confirmed by liver biopsy. Treatment with high-dose intravenous methylprednisolone is highly effective, achieving complete resolution in over 80% of cases. Chronic rejection — a rare but graft-threatening progressive ductopenia — is prevented by meticulous immunosuppression adherence.
Infection Prevention
Immunosuppression that prevents rejection simultaneously impairs the body's ability to fight infection. The highest-risk period is the first 3 months post-transplant. Prophylactic antivirals (valganciclovir against CMV), antifungals (fluconazole), and antibiotics (trimethoprim-sulfamethoxazole against PCP pneumonia) are prescribed routinely. All recipients must receive annual influenza vaccination, pneumococcal vaccination, and avoid live vaccines permanently while immunosuppressed.
Metabolic Complications
Calcineurin inhibitors (tacrolimus, cyclosporine) cause a cluster of metabolic effects: new-onset diabetes after transplant (NODAT) in 10–20%, hypertension in 60–70%, hyperlipidaemia in 40%, and chronic kidney disease in 15–20% at 5 years. These are managed proactively through regular monitoring and early intervention — an important reason why all our transplant recipients have scheduled annual metabolic reviews regardless of symptom status.
Cancer Surveillance
Long-term immunosuppression carries a 2–3 fold increased risk of de novo malignancies compared to the general population, particularly skin cancers and post-transplant lymphoproliferative disorder (PTLD). Annual dermatology review, sun protection counselling, and avoidance of tobacco are mandatory for all transplant recipients. Recipients transplanted for HCC require continued tumour marker and imaging surveillance per established HCC recurrence protocols.
A 2023 systematic review in the American Journal of Transplantation assessed quality of life (QoL) outcomes in over 4,200 LDLT recipients at 5 years post-transplant. Physical functioning, social participation, psychological wellbeing, and return to employment scores were all comparable to age-matched general population controls. The overwhelming majority of recipients — over 85% — reported that transplantation had met or exceeded their expectations for quality of life improvement. This is the true measure of what LDLT achieves.